Actively Recruiting
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
Led by Smart Immune SAS · Updated on 2023-03-06
36
Participants Needed
1
Research Sites
265 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitor (HTLP)) injection to accelerate immune reconstitution after T cell depleted allogeneic hematopoietic stem cell transplantation (HSCT) in adult and pediatric patients with hematological malignancies.
CONDITIONS
Official Title
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients with high-risk acute leukemia or myelodysplastic syndrome eligible for T cell depleted allogeneic HSCT
- Age 18 years or older with clinical condition suitable for allogeneic stem cell transplant
- Karnofsky performance status 70% or higher before conditioning
- Normal organ function prior to conditioning
- Pediatric patients with high-risk acute leukemia eligible for T cell depleted allogeneic HSCT
- Age under 18 years at inclusion
- No matched sibling donor available
- Lansky or Karnofsky performance status 70% or higher before conditioning
- Normal organ function prior to conditioning
You will not qualify if you...
- Use of an HLA matched cord blood or haploidentical donor
- Previous allogeneic stem cell transplant
- Treatment with another cellular therapy within one month before inclusion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Memorial Sloan Kettering Cancer Center (MSKCC)
New York, New York, United States, 10065
Actively Recruiting
Research Team
F
Frédéric LEHMANN, MD
CONTACT
L
Laura SIMONS, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here